MBIO Mustang Bio, Inc. Stock Quote

MBIO [NASD]

Index	-	P/E	-	EPS (ttm)	-0.85	Insider Own	1.50%	Shs Outstand	91.14M	Perf Week	-12.86%
Market Cap	120.12M	Forward P/E	-	EPS next Y	-0.79	Insider Trans	10.67%	Shs Float	75.63M	Perf Month	-34.76%
Income	-66.90M	PEG	-	EPS next Q	-0.19	Inst Own	29.20%	Short Float	3.94%	Perf Quarter	-42.45%
Sales	-	P/S	-	EPS this Y	11.30%	Inst Trans	0.54%	Short Ratio	2.58	Perf Half Y	-56.89%
Book/sh	1.34	P/B	0.91	EPS next Y	-4.10%	ROA	-50.50%	Target Price	8.40	Perf Year	-72.83%
Cash/sh	1.23	P/C	0.99	EPS next 5Y	-	ROE	-54.70%	52W Range	1.15 - 4.90	Perf YTD	-26.51%
Dividend	-	P/FCF	-	EPS past 5Y	-45.20%	ROI	-	52W High	-75.10%	Beta	1.57
Dividend %	-	Quick Ratio	11.70	Sales past 5Y	-	Gross Margin	-	52W Low	6.09%	ATR	0.13
Employees	62	Current Ratio	11.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	23.94	Volatility	8.34% 8.48%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	17.50%	Profit Margin	-	Rel Volume	0.54	Prev Close	1.22
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.16M	Price	1.22
Recom	1.60	SMA20	-20.60%	SMA50	-33.37%	SMA200	-53.79%	Volume	336,776	Change	0.00%

May-18-21

Initiated

BTIG Research

Buy

$11

Oct-02-20

Initiated

B. Riley FBR

Buy

Nov-20-19

Initiated

Cantor Fitzgerald

Overweight

Aug-13-19

Initiated

H.C. Wainwright

Buy

Jun-21-19

Initiated

Cantor Fitzgerald

Overweight

Dec-21-17

Initiated

Oppenheimer

Outperform

$18

Jan-25-22 07:10AM	FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder Benzinga -6.15%
Jan-24-22 05:00PM	Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (XSCID) in Previously Transplanted Patients GlobeNewswire
Jan-07-22 02:05PM	Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR GlobeNewswire
Jan-05-22 08:30AM	Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences GlobeNewswire -5.26%
Dec-16-21 08:30AM	Mustang Bio Added to the NASDAQ Biotechnology Index GlobeNewswire
Dec-13-21 09:00AM	Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia GlobeNewswire -11.59%
Dec-09-21 08:30AM	Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia GlobeNewswire
Dec-06-21 07:30AM	Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation Simply Wall St.
Nov-12-21 08:05AM	Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights GlobeNewswire
Nov-10-21 08:00AM	Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency GlobeNewswire
Nov-09-21 09:02AM	3 Penny Stocks Insiders Are Buying Benzinga +6.69%
Nov-04-21 09:24AM	Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-01-21 10:19AM	Mustang Bio Secures $2M NIH Grant For CAR T Cell Therapy Development Benzinga +6.25%
08:30AM	Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas GlobeNewswire
Oct-06-21 10:28AM	Here's What Mustang Bio, Inc.'s (NASDAQ:MBIO) Shareholder Ownership Structure Looks Like Simply Wall St.
Oct-04-21 09:57AM	Mustang Bio, Inc. (MBIO): Hedge Funds In Wait-and-See Mode Insider Monkey -6.82%
Sep-30-21 08:30AM	Mustang Bio to Participate in Chardans Virtual 5th Annual Genetic Medicines Conference GlobeNewswire
Sep-28-21 08:30AM	Mustang Bio Announces MB-101 (IL13R2targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences GlobeNewswire
Sep-24-21 06:10AM	Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy? Zacks
Sep-09-21 08:30AM	Mustang Bio to Participate in Three September 2021 Investor Conferences GlobeNewswire
Aug-16-21 04:01PM	Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights GlobeNewswire
Aug-13-21 10:03AM	Mustang Bio, Mayo Clinic Join Forces On New CAR T Tech In Tumor Settings Benzinga
Aug-12-21 04:45PM	Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology GlobeNewswire
Aug-07-21 03:50AM	Trade Alert: The President Of Mustang Bio, Inc. (NASDAQ:MBIO), Manuel Litchman, Has Just Spent US$251k Buying 9.9% More Shares Simply Wall St.
Aug-02-21 10:31AM	Mustang Bio's Gene Therapy For Genetic Immunodeficiency Receives European PRIME Tag Benzinga
08:00AM	Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants GlobeNewswire
Jul-14-21 09:11AM	15 Best Penny Stocks to Buy Now Insider Monkey
Jun-17-21 08:00AM	Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive GlobeNewswire
Jun-16-21 08:30AM	Mustang Bio to Present at the Raymond James Human Health Innovation Conference GlobeNewswire
Jun-15-21 04:32AM	Here's Why We're Not Too Worried About Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation Simply Wall St.
Jun-11-21 07:28AM	Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial Benzinga
06:30AM	Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia GlobeNewswire
Jun-07-21 08:00AM	Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia GlobeNewswire
May-18-21 04:03PM	Why Mustang Bio Stock Galloped Higher Today Motley Fool +10.84%
09:26AM	BTIG Sees 260% Upside In Mustang Bio With PT of $11; Early-Stage MB-101 Starts Dosing Brain Tumor Patients Benzinga
08:00AM	Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13R2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors GlobeNewswire
May-14-21 04:30PM	Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights GlobeNewswire
May-12-21 12:45PM	Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress GlobeNewswire
May-10-21 07:30AM	Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy GlobeNewswire
Apr-21-21 08:00AM	Mustang Bio to Participate in Chardans 5th Annual Genetic Medicines Manufacturing Summit GlobeNewswire
Apr-16-21 05:20AM	Could The Mustang Bio, Inc. (NASDAQ:MBIO) Ownership Structure Tell Us Something Useful? Simply Wall St.
Mar-24-21 04:30PM	Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights GlobeNewswire -7.25%
Mar-04-21 08:00AM	Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences GlobeNewswire -7.42%
Feb-26-21 08:00AM	Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® GlobeNewswire
Feb-15-21 01:39AM	Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price Simply Wall St.
Feb-02-21 07:30AM	Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (XSCID) GlobeNewswire
Jan-05-21 08:30AM	Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences GlobeNewswire +6.58%
Dec-22-20 01:17PM	These 2 Penny Stocks Are Poised for a Massive Rally, Say Analysts TipRanks
Dec-21-20 08:00AM	Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13R2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors GlobeNewswire +5.52%
Dec-18-20 12:14AM	Non-Executive Director Lindsay Rosenwald Just Bought 100% More Shares In Mustang Bio, Inc. (NASDAQ:MBIO) Simply Wall St.
Dec-14-20 09:10PM	Is MBIO A Good Stock To Buy Now? Insider Monkey
Dec-07-20 07:30AM	Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma GlobeNewswire -19.01%
Dec-04-20 08:45AM	Is the Options Market Predicting a Spike in Mustang Bio (MBIO) Stock? Zacks
Dec-01-20 08:00AM	Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma GlobeNewswire
Nov-24-20 08:00AM	Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (XSCID) GlobeNewswire
Nov-23-20 08:00AM	Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency GlobeNewswire
Nov-09-20 10:29AM	Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely? Simply Wall St.
Nov-06-20 04:20PM	Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights GlobeNewswire
Nov-04-20 09:25AM	Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting GlobeNewswire +5.05%
Oct-26-20 08:00AM	Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer GlobeNewswire -9.83%
Oct-08-20 08:00AM	Mustang Bio Announces MB-105 Data Selected for Presentation at the Virtual 27th Annual Prostate Cancer Foundation Scientific Retreat GlobeNewswire +5.06%
Oct-07-20 04:15PM	Horizon Technology Finance Provides Third Quarter 2020 Portfolio Update PR Newswire
Oct-06-20 08:00AM	Mustang Bio Licenses LentiBOOST Technology from SIRION Biotech GlobeNewswire
Oct-01-20 08:00AM	Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy) GlobeNewswire
Sep-22-20 08:00AM	Mustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency (XSCID) in Previously Transplanted Patients GlobeNewswire
Sep-18-20 09:17AM	Is the Options Market Predicting a Spike in Mustang Bio (MBIO) Stock? Zacks +7.78%
Sep-10-20 08:00AM	Mustang Bio to Participate in Three September 2020 Virtual Investor Conferences GlobeNewswire
Sep-02-20 08:00AM	Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants GlobeNewswire
Aug-31-20 08:00AM	Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients GlobeNewswire
Aug-24-20 02:01PM	What You Need To Know About Mustang Bio, Inc.'s (NASDAQ:MBIO) Investor Composition Simply Wall St. -8.10%
Aug-18-20 08:53AM	Do Options Traders Know Something About Mustang Bio (MBIO) Stock We Don't? Zacks
Aug-17-20 08:00AM	Mustang Bio to Present at the Virtual Fortress Biotech Corporate Access Summit GlobeNewswire +13.92%
08:00AM	Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency GlobeNewswire
Aug-12-20 03:31PM	Oppenheimer: These 3 Penny Stocks Could Rally Over 100% TipRanks
Aug-10-20 04:30PM	Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights GlobeNewswire
Jul-21-20 08:52AM	Mustang Bio (MBIO) Looks Good: Stock Adds 5.8% in Session Zacks -5.43%
Jun-25-20 10:15AM	Hedge Funds Have Never Been This Bullish On Mustang Bio, Inc. (MBIO) Insider Monkey
Jun-17-20 08:39AM	Do Options Traders Know Something About Mustang Bio (MBIO) Stock We Don't? Zacks -7.06%
Jun-11-20 09:00AM	Mustang Bio Announces Pricing of Public Offering of Common Stock GlobeNewswire -29.35%
08:51AM	Mustang Bio (MBIO) Jumps: Stock Rises 8.2% Zacks
Jun-10-20 04:01PM	Mustang Bio Announces Proposed Public Offering of Common Stock GlobeNewswire +8.24%
Jun-04-20 08:30AM	Mustang Bio to Host Virtual Annual Meeting of Stockholders GlobeNewswire +5.35%
May-25-20 06:39AM	Trade Alert: The President Of Mustang Bio, Inc. (NASDAQ:MBIO), Manuel Litchman, Has Just Spent US$533k Buying 545% More Shares Simply Wall St.
May-21-20 08:32AM	Is Mustang (MBIO) Stock a Solid Choice Right Now? Zacks
May-12-20 08:00AM	Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy GlobeNewswire -7.52%
May-11-20 04:20PM	Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights GlobeNewswire +14.34%
Apr-20-20 08:00AM	Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency GlobeNewswire
Apr-07-20 12:44PM	Before You Buy Mustang Bio, Inc. (NASDAQ:MBIO), Consider Its Volatility Simply Wall St. -7.69%
Mar-16-20 04:45PM	Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights GlobeNewswire
Mar-15-20 11:19AM	3 Stocks That Should Bounce Back Once Coronavirus Fears Fade TipRanks
Feb-18-20 08:00AM	Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106 GlobeNewswire
Jan-22-20 08:30AM	Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020 GlobeNewswire
Dec-27-19 12:00PM	Mustang Bio, Inc. (MBIO) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Dec-20-19 02:59PM	Hedge Funds Are Done Buying Mustang Bio, Inc. (MBIO) Insider Monkey
Dec-09-19 07:30AM	Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency GlobeNewswire -17.66%
Dec-02-19 08:30AM	Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference GlobeNewswire
Nov-12-19 07:30AM	Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire
Nov-06-19 09:15AM	Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting GlobeNewswire
Oct-24-19 08:30AM	Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma GlobeNewswire
Oct-10-19 08:00AM	Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma GlobeNewswire

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Achenbach Brian	SVP, Fin. & Corp. Controller	Dec 14	Sale	1.83	4,374	8,004	144,729	Dec 16 04:30 PM
Litchman Manuel MD	President and CEO	Oct 27	Buy	2.24	65,000	145,600	1,027,987	Nov 08 04:35 PM
Achenbach Brian	SVP, Fin. & Corp. Controller	Oct 12	Sale	2.28	4,450	10,146	126,603	Oct 21 04:32 PM
Litchman Manuel MD	President and CEO	Jul 30	Buy	2.91	86,206	250,859	960,241	Aug 05 04:23 PM
Achenbach Brian	SVP, Fin. & Corp. Controller	Apr 09	Sale	3.36	2,423	8,141	131,053	Apr 16 04:32 PM
Litchman Manuel MD	President and CEO	Mar 05	Buy	3.12	165,562	516,553	825,408	Mar 15 06:35 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience